De Luca L, Valgimigli M (2020) Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. Eur Heart J - Cardiovasc Pharmacotherapy 7:352–359. https://doi.org/10.1093/ehjcvp/pvaa107

Article  Google Scholar 

Piccolo R, Oliva A, Avvedimento M, Franzone A, Windecker S, Valgimigli M, Esposito G, Jüni P (2021) Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis. EuroIntervention 17. https://doi.org/10.4244/EIJ-D-20-01197

Cao D, Chandiramani R, Chiarito M, Claessen BE, Mehran R (2021) Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. Eur Heart J 42:339–351. https://doi.org/10.1093/eurheartj/ehaa824

Article  PubMed  Google Scholar 

Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabrò P, Terracciano F, Andreotti F, Patti G, De Caterina R et al (2024) Antithrombotic therapy in high bleeding risk, part I: percutaneous cardiac interventions. JACC Cardiovasc Interv 17:2197–2215. https://doi.org/10.1016/j.jcin.2024.08.022

Article  PubMed  Google Scholar 

Valgimigli M, Aboyans V, Angiolillo D, Atar D, Capodanno D, Halvorsen S, James S, Jüni P, Kunadian V, Landi A et al (2023) Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease. Eur Heart J Cardiovasc Pharmacother 9:462–496. https://doi.org/10.1093/ehjcvp/pvad032

Article  CAS  PubMed  Google Scholar 

Capodanno D, Milluzzo RP, Angiolillo DJ (2019) Intravenous antiplatelet therapies (glycoprotein iib/iiia receptor inhibitors and cangrelor) in percutaneous coronary intervention: from Pharmacology to indications for clinical use. Ther Adv Cardiovasc Dis 13:1753944719893274. https://doi.org/10.1177/1753944719893274

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E et al (2013) Effect of platelet Inhibition with Cangrelor during PCI on ischemic events. N Engl J Med 368:1303–1313. https://doi.org/10.1056/NEJMoa1300815

Article  CAS  PubMed  Google Scholar 

Stone GW, Généreux P, Harrington RA, White HD, Gibson CM, Steg PG, Hamm CW, Mahaffey KW, Price MJ, Prats J et al (2018) Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor Inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial. Eur Heart J 39:4112–4121. https://doi.org/10.1093/eurheartj/ehy562

Article  CAS  PubMed  PubMed Central  Google Scholar 

Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D et al (2017) International expert consensus on switching platelet P2Y12 receptor inhibiting therapies. Circulation 136:1955–1975. https://doi.org/10.1161/CIRCULATIONAHA.117.031164

Article  CAS  PubMed  Google Scholar 

Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS (2008) Transitioning patients from Cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 121:527–534. https://doi.org/10.1016/j.thromres.2007.05.020

Article  CAS  PubMed  Google Scholar 

Franchi F, Rollini F, Ortega-Paz L, Been L, Giordano S, Galli M, Ghanem G, Garabedian H, Al Saleh T, Uzunoglu E et al (2023) Switching from Cangrelor to Prasugrel in patients undergoing percutaneous coronary intervention. JACC: Cardiovasc Interventions 16:2528–2539. https://doi.org/10.1016/j.jcin.2023.08.009

Article  Google Scholar 

Rymer JA, Bhatt DL, Angiolillo DJ, Diaz M, Garratt KN, Waksman R, Edwards L, Tasissa G, Salahuddin K, El-Sabae H et al (2022) Cangrelor use patterns and transition to oral P2Y12 inhibitors among patients with myocardial infarction: initial results from the CAMEO registry. J Am Heart Association 11:e024513. https://doi.org/10.1161/JAHA.121.024513

Article  Google Scholar 

De Luca L, Calabrò P, Capranzano P, Di Mario C, Chirillo F, Rolfo C, Menozzi A, Menichelli M, Bolognese L, Musumeci G et al (2023) Safety of Cangrelor and transition to oral P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study. Eur Heart J Open 3. https://doi.org/10.1093/ehjopen/oead076

Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J et al (2019) Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 140:240–261. https://doi.org/10.1161/circulationaha.119.040167

Article  PubMed  PubMed Central  Google Scholar 

Qamar A, Bhatt DL (2017) Optimizing the use of Cangrelor in the real world. Am J Cardiovasc Drugs 17:5–16. https://doi.org/10.1007/s40256-016-0192-1

Article  CAS  PubMed  Google Scholar 

Galli M, Cortellini G, Occhipinti G, Rossini R, Romano A, Angiolillo DJ (2024) Aspirin hypersensitivity in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol 84:1748–1766. https://doi.org/10.1016/j.jacc.2024.05.084

Article  PubMed  Google Scholar 

Rossini R, Masiero G, Fruttero C, Passamonti E, Calvaruso E, Cecconi M, Carlucci C, Mojoli M, Guido P, Talanas G et al (2020) Antiplatelet therapy with Cangrelor in patients undergoing surgery after coronary stent implantation: A Real-World bridging protocol experience. TH Open 4:e437–e445. https://doi.org/10.1055/s-0040-1721504

Article  PubMed  PubMed Central  Google Scholar 

De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ (2021) Cangrelor: clinical data, contemporary use, and future perspectives. J Am Heart Association 10:e022125. https://doi.org/10.1161/JAHA.121.022125

Article  Google Scholar 

Franchi F, Rollini F, Rivas A, Wali M, Briceno M, Agarwal M, Shaikh Z, Nawaz A, Silva G, Been L et al (2019) Platelet Inhibition with Cangrelor and crushed Ticagrelor in patients with ST-Segment–Elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 139:1661–1670. https://doi.org/10.1161/CIRCULATIONAHA.118.038317

Article  CAS  PubMed  Google Scholar 

Hochholzer W, Kleiner P, Younas I, Valina CM, Löffelhardt N, Amann M, Bömicke T, Ferenc M, Hauschke D, Trenk D et al (2017) Randomized comparison of oral P2Y12-Receptor inhibitor loading strategies for transitioning from cangrelor: the ExcelsiorLOAD2 trial. JACC: Cardiovasc Interventions 10:121–129. https://doi.org/10.1016/j.jcin.2016.10.004

Article  Google Scholar 

Franchi F, Ortega-Paz L, Rollini F, Galli M, Been L, Ghanem G, Shalhoub A, Ossi T, Rivas A, Zhou X et al (2023) Cangrelor in patients with coronary artery disease pretreated with Ticagrelor. JACC: Cardiovasc Interventions 16:36–46. https://doi.org/10.1016/j.jcin.2022.10.034

Article  Google Scholar 

Rymer J, Alhanti B, Kemp S, Bhatt DL, Kochar A, Angiolillo DJ, Diaz M, Garratt KN, Wimmer NJ, Waksman R et al (2024) Risk of bleeding among Cangrelor-Treated patients administered upstream P2Y12 inhibitor therapy: the CAMEO registry. J Soc Cardiovasc Angiography Interventions 3. https://doi.org/10.1016/j.jscai.2023.101202

Gargiulo G, Cirillo P, Sperandeo L, Castiello DS, Manzi L, Forzano I, Florimonte D, Simonetti F, Canonico ME, Avvedimento M et al (2025) Pharmacodynamic effects of Cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII registry. EuroIntervention 21:560–570. https://doi.org/10.4244/eij-d-24-00757

Article  PubMed  Google Scholar 

Gargiulo G, Marenna A, Sperandeo L, Manzi L, Avvedimento M, Simonetti F, Canonico ME, Paolillo R, Spinelli A, Borgia F et al (2023) Pharmacodynamic effects of Cangrelor in elective complex PCI: insights from the POMPEII registry. EuroIntervention 18:1266–1268. https://doi.org/10.4244/eij-d-22-00594

Article  PubMed  PubMed Central  Google Scholar 

Rymer J, Pichan C, Page C, Alhanti B, Bhatt DL, Kochar A, Angiolillo DJ, Diaz M, Wimmer NJ, Waksman RON et al (2024) The use of Cangrelor in cardiogenic shock: insights from the CAMEO registry. J Card Fail 30:1233–1240. https://doi.org/10.1016/j.cardfail.2024.08.003

Article  PubMed  Google Scholar 

Motovska Z, Hlinomaz O, Mrozek J, Kala P, Geisler T, Hromadka M, Akin I, Precek J, Kettner J, Cervinka P et al (2024) Cangrelor versus crushed Ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial. EuroIntervention 20:e1309–e1318. https://doi.org/10.4244/EIJ-D-24-00203

Article  PubMed  Google Scholar 

Galli M, Migliaro S, Rodolico D, Piccinni GDIS, Restivo C, Andreotti A, Vergallo F, Montone R, Besis RA (2022) Intracoronary bolus of glycoprotein iib/iiia inhibitor as bridging or adjunctive strategy to oral P2Y12 inhibitor load in the modern setting of ST-elevation myocardial infarction. Minerva Cardiol Angiol 70:697–705. https://doi.org/10.23736/s2724-5683.21.05669-6

Article  PubMed  Google Scholar 

Oliva A, Cao D, Spirito A, Nicolas J, Pileggi B, Kamaleldin K, Vogel B, Mehran R (2023) Personalized approaches to antiplatelet treatment for cardiovascular diseases: an umbrella review. Pharmgenomics Pers Med 16:973–990. https://doi.org/10.2147/pgpm.S391400

Article  CAS  PubMed  PubMed Central  Google Scholar